Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | FABP3 | P05413 | 5/20 | 0.56 |
| ▸ | TERT | O14746 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL741627 | 0.98 | FAAH (0.57) | FAAHFABP3TERTPTPN1PPARG | |
| Propane SCHEMBL28144123 | 0.98 | FAAH (0.57) | FAAHFABP3TERTPTPN1PPARG | |
| Propane SCHEMBL26102539 | 0.97 | FAAH (0.55) | FAAHFABP3TERTPTPN1PPARG | |
| Phosphoric Acid SCHEMBL1223979 | 0.94 | FABP3 (0.54) | FAAHFABP3TERTPTPN1PPARG | |
| Phosphoric Acid SCHEMBL28049027 | 0.94 | FABP3 (0.54) | FAAHFABP3TERTPTPN1PPARG | |
| SCHEMBL16061965 | 0.90 | KMT2A (0.50) | FABP3PTPN1PPARGPPARDPPARA | |
| SCHEMBL1720049 | 0.90 | KMT2A (0.50) | FABP3PTPN1PPARGPPARDPPARA | |
| Propane SCHEMBL29226175 | 0.88 | KMT2A (0.48) | FABP3PTPN1PPARGPPARDPPARA | |
| Propane SCHEMBL743689 | 0.88 | KMT2A (0.48) | FABP3PTPN1PPARGPPARDPPARA | |
| Propane SCHEMBL322960 | 0.88 | KMT2A (0.48) | FABP3PTPN1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640212-A1 | FUNCTIONALIZED LIPOSOMAL COMPLEX, PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION AND RELATED USES | Marjan Industria E Comercio Ltda (BR) | 2025-10-29 | — | — | EP | claimed |
| WO-2024130374-A1 | FUNCTIONALIZED LIPOSOMAL COMPLEX, PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION AND RELATED USES | MARJAN INDÚSTRIA E COMÉRCIO LTDA (BR) | 2024-06-27 | — | — | WO | claimed |
| CN-112716914-B | Albumin-coated cabazitaxel cation nano lipid carrier and preparation method thereof | 成都大学 | 2022-11-25 | — | — | CN | claimed |
| EP-2968598-B1 | TREATMENT FOR EXPOSURE TO NERVE AGENT | UNIV GEORGETOWN (US) | 2020-05-27 | — | — | EP | claimed |
| EP-1633327-B1 | METHOD FOR IMPROVING STABILITY AND SHELF-LIFE OF LIPOSOME COMPLEXES | UNIV GEORGETOWN (US) | 2010-08-11 | — | — | EP | claimed |
| EP-4745237-A1 | RNAI AGENT FOR INHIBITING EXPRESSION OF KETOHEXOKINASE AND USE THEREOF | YUN HO BIO CO., LTD (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4722363-A1 | RNAI AGENT FOR INHIBITING ANGPTL3 EXPRESSION AND USE THEREOF | YUN HO BIO CO., LTD (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-4640212-A1 | FUNCTIONALIZED LIPOSOMAL COMPLEX, PHARMACEUTICAL COMPOSITION, COSMETIC COMPOSITION AND RELATED USES | Marjan Industria E Comercio Ltda (BR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4563142-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | National University Corporation Hokkaido University (JP) | 2025-06-04 | — | — | EP | disclosed |
| US-20240358837-A1 | Amorphous Photosensitizing Particles, Methods For The Preparation Thereof, And Methods For The Use Thereof | UNIV MARYLAND (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20040259159-A1 | Role of LDL receptor protein-1 (LRP-1) in Alzheimer's disease | ZLOKOVIC BERISLAV V (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1001750-B1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBALE CHARGE OF LAMELLAR STRUCTURE | CEVA SANTE ANIMALE (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1404298-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003000227-A2 | A METHOD FOR PREPARATION OF VESICLES LOADED WITH BIOLOGICAL MATERIAL AND DIFFERENT USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-01-03 | — | — | WO | disclosed |
| US-6096335-A | COMPLEX CONTAINING LIPID | BIOVECTOR THERAPEUTICS, S.A. (FR) | 2000-08-01 | — | — | US | disclosed |
| EP-1001750-A1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBALE CHARGE OF LAMELLAR STRUCTURE | Biovector Therapeutics S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006026-A9 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBAL CHARGE OF LAMELLAR STRUCTURE | BIOVECTOR THERAPEUTICS SA (FR) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999006026-A1 | STABLE PARTICULATE COMPLEXES WITH NEUTRAL OR NEGATIVE GLOBAL CHARGE OF LAMELLAR STRUCTURE | BIOVECTOR THERAPEUTICS (S.A.) (FR) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | FABP1, RHOA, STAT6 | FAAH 505/4885FABP3 155/4885TERT 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.